Table 1. Patients' baseline characteristics.
| Number of patients | 132 |
| Median age (years) [range] | 63.5 [26–85] |
| Gender (male/female) | 86/46 |
| Primary tumour site | |
| Colon | 78 |
| Sigma-rectum junction | 19 |
| Rectum | 31 |
| Other* | 4 |
| EGFR targeted therapy | |
| Cetuximab | 109 |
| Panitumumab | 23 |
| Previous chemotherapy (%) | |
| Irinotecan based | 117 (88.6%) |
| Fluoropyrimidine/capecitabine based | 115 (87.1%) |
| Oxaliplatin based | 105 (79.5%) |
| No. of previous cancer treatments for advanced disease prior anti-EGFR moAbs (%) | |
| None | 13 (9.8%) |
| One | 19 (14.4%) |
| Two | 65 (49.2%) |
| Three | 29 (22.0%) |
| More than three | 6 (4.5%) |
| Cutaneous toxicity (%) | |
| 0 | 21 (15.9%) |
| 1 | 67 (50.7%) |
| 2–3 | 37 (28.0%) |
| Unknown | 7 (5.3%) |
*
Other: in two cases, primary tumor site was small bowel, in one case duodenum and in one case primary tumor sites were multiple (colon and rectum).